Xenon Pharmaceuticals Inc.

US$39.17As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:XENEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 17.78%
Div yield —
ROE (43.62%)
Biotechnology
Beta (5Y) 0.08
PE TTM —
TSR TTM (6.56%)
Mkt cap US$3.793B
ROIC (29.18%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$46
16.32%
(23.70%)
Hold 3|9|3|12|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.80
0.86
0.89
0.97
6.29%
19.81%
13.83%
22.88%
Revenue$M
300.8
297.3
297.2
303.0
5.34%
2.24%
(1.95%)
(1.35%)
Peers (US$3.793B)
Cap (US$)
PE
654.6M
—
3.756B
35.19x
Capital
TTM
5Y
10Y
Leveragex
1.299
0.083
0.074
EBIT/Intx
0.796
0.060
0.063
Own earn%
(46.18)
130.73
141.15
Sh yield%
33.79
34.13
33.70
Owners
Insiders/Inst%
10.64
86.97
Short interest%
3.92
SBC / revenue%
5.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
24–29
$1 testx
—
Incr. ROIC%
13